SCHEMBL20831764

SCHEMBL20831764

CC[C@@H]1CN(C(=O)OC(C)(C)C)CCN1c1cc[nH]c(=O)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.41
USP30 Q70CQ3 2/20 0.41
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
PARP1 P09874 1/20 0.38
ADAMTS5 Q9UNA0 2/20 0.38
SMARCA2 P51531 1/20 0.37
SMARCA4 P51532 1/20 0.37
PBRM1 Q86U86 1/20 0.37
ADAM17 P78536 1/20 0.37
BRD4 O60885 1/20 0.37
GPR119 Q8TDV5 5/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TP53 P04637 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818753 0.84 HRH3 (0.40) HRH3PARP1ADAMTS5BRD4
SCHEMBL20831763 0.82 IDO1 (0.41) USP30KDM4EMAPTTHRBPARP1
SCHEMBL31484639 0.81 GPR119 (0.52) USP30KDM4EPARP1SMARCA2SMARCA4
SCHEMBL38665341 0.80 USP30 (0.43) USP30MAPTTHRBPARP1ADAMTS5
SCHEMBL12336485 0.80 ALDH1A1 (0.46) USP30KDM4EMAPTPARP1GPR119
SCHEMBL31585294 0.78 ADAMTS5 (0.40) USP30KDM4EMAPTTHRBPARP1
SCHEMBL13799383 0.78 HRH3 (0.56) HRH3KDM4EMAPTTHRBGPR119
SCHEMBL12089736 0.78 GPR119 (0.40) MAPTPARP1GPR119
SCHEMBL38664308 0.75 GPR119 (0.41) PARP1ADAMTS5GPR119TP53
SCHEMBL14927206 0.75 MEN1 (0.45) USP30MAPTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 US disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN HRH3 1171/4885USP30 4765/4885KDM4E 3899/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN HRH3 1171/4885USP30 4765/4885KDM4E 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.